Dealing with the data deluge in high throughput screening by Skehan, Philip
Dealing with the data deluge in high
throughput screening
Philip Skehan,
Andes Pharmaceuticals, Inc., 26520 Northeast 15th Street, Redmond, WA 98053,
USA
Numerical taxonomy and pattern recognition analysis oå er power-
ful tools that can greatly reduce the information burden of
multiple-assay screening programs. These methods can be used
to rationally design prescreens, identify assays that have similar
chemical response patterns, select reporter assays for chemical
response groups, evaluate drug selectivity, and predict a drug’s
likely mechanism of action. When combined with assays designed
to identify lead compounds that have characteristics likely to cause
failure at a later and more expensive stage of development, a simple
three-stage primary discovery process consisting of a rational
prescreen, reporters, and clinical failure assay can reduce the
number of required culture wells by more than 20-fold and can
eliminate all but 1–2 drugs per 1000 tested as leads for further
evaluation and development.
Introduction
The extraordinary volume of data generated by high
throughput screening has shifted the bottlenecks in drug
discovery from compound acquisition and screening to
the management and analysis of data. This presentation
explores two questions. How can biological data be used
to make the screening processsmaller, simpler, faster, and
cheaper? And how can biological data be used to better
prioritize lead compounds for further development?
Numerical taxonomy and pattern recognition o￿ er
powerful tools for addressing these questions, and can
greatly reduce the information burden of multi-assay
screening programs.
Identifying chemical response groups
Hundreds of di￿ erent drug discovery assays are now
available. With cancer, there are more than 300 di￿ erent
human neoplastic diseases, each a potential screening
target. Do we need to screen against all of them? Or, is
it possible that some cancers may be similar enough to
one another in their chemical response patterns that a
single assay might serve as a reporter for an entire group
of cell lines?
To explore this issue, we performed similarity analyses
(Pearson’s and Kendall’s tau) and three types of cluster
analysis (city block, Pearson’s coe￿ cient, and Kendall’s
tau taxonomic distance metrics using both average and
median linkage methods for each) of the chemical re-
sponse patterns for 72 tumour lines in tissue culture [1, 2].
Most of the lines were of human origin, but some animal
lines were used as well. Nearly 400 bioactive compounds
were screened against the cell lines in dose± response
mode using a homogeneous propidium iodide assay
that measures the ¯ uorescence emission of dye molecules
intercalated into double stranded regions of RNA and
DNA [3]. The compounds encompassed a wide range of
chemical structures and mechanisms of action.
As the cell lines employed had markedly di￿ erent dou-
bling times, conventional methods for quantifying drug
e￿ ects, such as I50 or T =C, could not be used because the
biological signi® cance of such indices is proportional to
growth rate. Instead, we calculated a response function
RF that allows e￿ cacy and potency to be compared for
cell lines with very di￿ erent growth rates [4, 5]. Three
measurements must be made to calculate RF: a time zero
sample Z at the start of an assay, and end of assay control
C and test T samples. If growth of the test cultures isnon-
negative …T 5Z†, RF is calculated as 100‰…T ¡ Z†=
…C ¡ Z†Š. If T < Z, then RF is calculated as
100‰…T ¡ Z†=ZŠ. Control cultures have an RF value of
‡100, total net growth inhibition has an RF value of 0,
and an RF value of ¡100 re¯ ects total culture extinction.
RF values greater than 100 signify a net growth stimula-
tion; an RF value between 0 and 100 represents net
growth inhibition, and a value between 0 and ¡100
indicates net cell killing.
For each compound, the test concentration was identi® ed
that produced maximum di￿ erential activity as indexed
by the mean absolute deviation of e￿ cacy values for all
cell lines. At this concentration, a selectivity coe￿ cient
SE ˆ hRFi ¡ RF was calculated for each cell line by
subtracting the e￿ cacy value of a cell line RF from the
median e￿ cacy value hRFi of all cell lines.
E￿ cacy rather than potency was used for three reasons.
First, potency is an interpolation while e￿ cacy is a
measured value. Second, potency requires an arbitrary
activity criterion, such as total growth inhibition
…RF ˆ 0†, which is often not achieved with a ® xed assay
protocol; when the activity criterion is not achieved,
potency values must be either deleted from the database
or assigned an arti® cial value such as the highest or
lowest concentration tested. Assigned values can be in
error by orders of magnitude. Third, it is not uncommon
for the dose± response curve of one assay to just barely
achieve the activity criterion and the curve for another
assay to just barely fail to do so. Even though the two
curves are nearly superimposable, very large apparent
di￿ erences in potency can arise that are artefactual.
Ten di￿ erent chemical response groups were identi® ed,
each with its own unique chemical response pattern. The
number of cell lines in each group ranged from two to 16
with a median of 5.5. There were four cell lines that were
related to one or another of the ten groups, but not
strongly enough to meet the inclusion criterion, and there
were seven cell lines whose chemical response patterns
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results of the cluster and similarity analyses were essen-
tially identical, suggesting that the taxonomic conclusions
reached are robust.
Of the ten chemical response groups, six were considered
to be clinically relevant, while four were not. The six
clinically relevant groups varied considerably in their
sensitivity to the chemical screening library. Maximum
group median selectivity coe￿ cients ranged from a low of
62 to a high of 150. Similarly, the most resistant group
was selectively sensitive to just 79 compounds, while the
most sensitive group selectively responded to 271.
Reporter assays
The question now arose: is it necessary to screen against
all of the cell lines within a response group, or might
there exist a single cell line that can serve as a reporter for
the entire group? For each chemical response group,
compounds that were selectively active against the
group were rank ordered by median group selectivity
coe￿ cient SE from the highest selectivity to zero selectiv-
ity. The cell line was then identi® ed that recognized the
greatest number of compounds active at various selectiv-
ity levels ranging from 0 to over 100. SE values from 0 to
40 represent weak selectivity; from 40 to 80 represent
moderate selectivity; and greater than 80 represent
strong selectivity.
Four of the reporter lines had an accuracy of better than
90% at SE values of 20 or greater, and ® ve exceeded 90%
at an SE value of 40 or greater (® gure 1). The worst
behaving reporter line displayed an accuracy of more
than 80% at SE values of 40 or greater. These ® ndings
indicate that single reporter assays can re¯ ect the beha-
vior of an entire chemical response group with reasonable
accuracy, and the use of reporter assays can greatly
reduce the screening burden of multi-assay screening
programs. The six reporter lines comprise the basis for
a selective toxicity screen, which operates in dose± reponse
mode.
Rationally designed prescreen
The identi® cation of reporter lines allowed us to reduce
our number of cancer assays by more than tenfold.
However, about 85% of the compounds tested were
inactive, with the result that a further reduction in the
screening burden could be achieved if a prescreen with
fewer than six cell lines could be constructed.
Prescreens can be rationally designed by statistically
determining the minimum number of assays required to
identify at a speci® ed level of accuracy those compounds
active against one or more of a larger group of screens.
Compounds were tested at a single high dose, and 50%
net growth inhibition was used as an activity criterion for
the prescreen analysis. The entire panel of cancer cell
lines was examined to determine the single cell line that
correctly identi® ed the greatest number of compounds
that were active against ® ve or more cell lines (noise level
of the system). That cell line was placed in the prescreen.
The remaining cell lines were then examined to ® nd the
next cell line that correctly identi® ed the greatest number
of active compounds not already identi® ed by the ® rst
cell line. That cell line was also placed in the prescreen.
This process was repeated iteratively until a prescreen
was developed that could predict activity within the
entire panel of lines with an accuracy of greater than
95%.
Surprisingly, this criterion was achieved with just two cell
lines. The two-cell line prescreen identi® ed the activity of
more than 800 compounds with an accuracy of 95.5%.
There were 0.7% false positive and 3.8% false negative
identi® cations.
Clinical failure assays
A common failing of many discovery screens is their
inability to identify lead compounds that have character-
istics likely to cause failure at a later and more expensive
stage of development. Simple in vitro assays predictive of
likely clinical failure can often be developed and included
as part of the primary drug discovery process. Such
clinical failure assays can quickly eliminate all but a
few competing leads from further development. With
cell-based screening, a clinical failure assay combined
with a rational prescreen and response group reporters
can eliminate all but 1± 2 drugs per 1000 tested as leads
for further evaluation and development.
One of the major reasons for the clinical failure of anti-
cancer drugs is the survival of residual tumour burden.
Most traditional anticancer drugs act more as growth
inhibitors than as target-eradicating cytotoxins. They
may well kill a portion of a tumour cell population, but
leave surviving cells that can grow back to life threaten-
ing proportions.
To identify drugs likely to permit the survival of residual
tumour burden, we developed a long term recovery
(LTR) assay that was incorporated as the third leg of
our primary discovery process [3]. In the LTR assay,
cultures are incubated with test compounds for 48 hours
in T25 ¯ asks at half-, just-, and supra-maximal concen- Figure 1. Accuracy of reporter lines.
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146trations. The drugs are then removed and the cultures
washed and fed with a fresh drug-free non-bicarbonated
growth medium that uses beta-glycerophosphate as a
bu￿ er. This medium, e.g. Gibco’s Nonbicarbonated
Growth Medium, is pH stable under atmospheric con-
ditions, does not require a CO2-enriched environment,
and contains phenol red as a colorimetric visual pH
indicator [6]. The ¯ asks are capped tightly, and placed
in a 378C incubator, where they are incubated for 60
days or until cellular regrowth is obvious.
There are two end points in the LTR assay: metabolic
and proliferative. Metabolic recovery is monitored by
visual inspection three times a week. Where metaboli-
cally surviving cells remain, their secretion of organic
acids gradually changes the colour of the growth med-
ium’s pH indicator dye from red to reddish-orange, to
orange and ® nally to yellow. When a colour change has
become obvious, cultures are inspected microscopically to
con® rm that the metabolism is the result of cellular
regrowth and not microbial contamination. The extent
of the pH change can be quantitated by measuring the
phenol red optical density at 560nm. Proliferative recov-
ery is quantitated by sulphorhodamine B protein optical
density or the propidium iodide ¯ uorescence from double
stranded RNA and DNA dye intercalation [3]. Control
¯ asks are collected at the time of drug addition and at the
end of the 48 hour incubation period. Test samples are
collected at these same times and after recovery has
occurred. RF values are calculated as described above.
In the LTR assay, 85% of high priority lead compounds
emerging from the selective toxicity screen failed to
completely erradicate tumour cells in culture, allowing
the cells subsequent regrowth. With most of the drugs
that failed the LTR assay, regrowth was obvious within
3± 5 days and sometimes within 1± 2 days.
Three-stage primary screening process
The primary screening process that Andes has adopted
consists of three stages: (1) an initial prescreen of two cell
lines with single high-dose testing; (2) a selective toxicity
screening panel in which test samples are screened in
dose± response mode against six reporter lines; and (3) a
long term recovery assay. For every 1000 compounds
that enter the screening process, about 150 are active in
the prescreen, 11 exhibit moderate or stong selectivity in
the selective toxicity screens, and 1.7 show no regrowth in
the LTR assay. The overall percentage of compounds
that progress to further development is about 0.17%
(® gure 2).
Multi-assay ￿ ngerprints
Multi-assay screening data can be visually represented as
bar graph ® ngerprints projecting to either the right or left
of a central reference value depending on whether an
assay is more or less sensitive to a test compound than is
the reference value. With mean graphs [7], log potencies
are ® rst determined for each assay, and the mean log
potency identi® ed. The mean log potency is then sub-
tracted from each individual value to produce an index of
di￿ erential sensitivity to the test compound. Negative
values of this di￿ erence indicate that an assay is more
sensitive than the mean, while positive values re¯ ect
resistance.
Similarly, an e￿ cacy ® ngerprint can be constructed by
® rst ® nding the median e￿ cacy for a set of RF values,
then subtracting individual RF values from this median.
Again, individual di￿ erences from the median are plotted
as bars projecting to the right for assays that are more
sensitive and to the left for assays that are more resistant
than the median.
Multi-assay ® ngerprints, ® rst used widely by the Na-
tional Cancer Institute, have proven valuable in a num-
ber of ways. They provide a simple method for presenting
complicated data in a manner that is easily understood
and which visually highlights patterns of di￿ erential
sensitivity (® gure 3).
Comparing ￿ ngerprints
Fingerprints can be compared both visually and numeri-
cally. The mean absolute di￿ erence (MAD) of two
® ngerprints provides a useful quantitative index of their
similarity or di￿ erence. Two compounds are compared
by summing the absolute di￿ erence of either their RF or
log potency values for each assay, then dividing this
sum by the number of assays. The more similar two
compounds are, the smaller their MAD will be.
Figure 2. The Andes cancer screening funnel.
Figure 3. Potency and e￿ cacy ￿ngerprints.
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147When the ® ngerprint of a test compound is compared
with the ® ngerprints of a large number of previously
tested drugs, a great deal of useful information can be
obtained. The best database matches often suggest the
likely mechanism of action of a new test compound.
Similarly, structural analogues are often very close
matches as well, and can suggest likely chemical struc-
tures of active components in crude natural product
extracts. Even when close matches are not analogues,
they sometimes possess similar molecular surface proper-
ties or three-dimensional conformations. The insight that
these similarities provides can be valuable in rational
drug design. Finally, ® ngerprint comparisons are extre-
mely useful in studies of structure-activity relationships.
Association coe￿ cients
Drug response patterns can also be qualitatively com-
pared using association coe￿ cients such as the simple
matching coe￿ cient SM and Jacard’s similarity coe￿ -
cient SJ. These association coe￿ cients compare two drugs
by determining on an assay by assay basis whether the
drugs are matched (a ˆ 11 or d ˆ 00) or mismatched
(b ˆ 01 or c ˆ 10) in their e￿ ects, where 1 represents
activity and 0 inactivity.
SM is well suited to the situation in which active and
inactive outcomes are roughly equal in frequency. It is
the ratio of matches to matches plus mismatches:
SM ˆ…a ‡d†=…a ‡b ‡c ‡d†. SJ ignores the doubly in-
active matches (00), and is well suited to the situation in
which active compounds are infrequent by comparison
with inactive: SJ ˆ a=…a ‡b ‡c†. A variety of other
association coe￿ cients are in common use as well [1, 2].
Association coe￿ cients can be used for the same purposes
as ® ngerprint comparisons, or can be used in conjunction
with ® ngerprints. For the two compounds shown in
® gure 4, SJ was 0.903 for selectivity values (SE) greater
than 0, and SJ 0.714 for selectivity values greater than 50.
Association coe￿ cients have a particularly useful prop-
erty: they can be used to compare multistate character-
istics de® ned by logic operators such as AND, OR, and
NOT. Thus an element for comparison could be: active
in assays 1± 10 NOT active in assays 11± 15 AND water
soluble at 1mM AND a hydrophobic interior AND(sen-
sitive to antimicrotubulars OR antifols). Such complex
activity criteria permit very sophisticated comparisons to
be performed.
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